LeMaitre Vascular, Inc. (NASDAQ:LMAT) Expected to Report Earnings of $0.32 Per Share

Stock analysts expect LeMaitre Vascular, Inc. (NASDAQ:LMAT – Get a rating) will report earnings per share of $0.32 for the current fiscal quarter, Zacks reports. Three analysts provided earnings estimates for LeMaitre Vascular. The highest EPS estimate is $0.35 and the lowest is $0.30. LeMaitre Vascular posted earnings of $0.28 per share in the same quarter last year, which would indicate a positive growth rate of 14.3% year over year. The company is expected to announce its next quarterly earnings report on Thursday, May 5.

On average, analysts expect LeMaitre Vascular to report annual earnings of $1.44 per share for the current fiscal year, with EPS estimates ranging from $1.39 to $1.50. For the next fiscal year, analysts expect the company to post earnings of $1.55 per share, with EPS estimates ranging from $1.48 to $1.63. Zacks Investment Research EPS averages are an average average based on a survey of sell-side research firms that provide coverage for LeMaitre Vascular.

LeMaitre Vascular (NASDAQ:LMAT – Get a rating) last released its results on Thursday, February 24. The medical device supplier reported earnings per share (EPS) of $0.28 for the quarter, missing Zacks’ consensus estimate of $0.31 per ($0.03). LeMaitre Vascular had a return on equity of 14.15% and a net margin of 18.21%. The company posted revenue of $39.50 million in the quarter, compared to $39.70 million expected by analysts. In the same quarter last year, the company achieved EPS of $0.34. The company’s revenue increased 5.2% year-over-year.

Several analysts have recently commented on LMAT shares. Zacks Investment Research downgraded shares of LeMaitre Vascular from a “hold” rating to a “sell” rating in a report on Wednesday, January 26. Barrington Research lowered its price target on LeMaitre Vascular shares from $62.00 to $54.00 in a report on Friday. One research analyst rated the stock with a sell rating, one gave the stock a hold rating, and three gave the stock a buy rating. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $61.80.

NASDAQ: LMAT traded down $0.10 in Friday’s midday session, hitting $45.77. The company’s stock had a trading volume of 1,854 shares, compared to an average volume of 83,845. LeMaitre Vascular has a fifty-two week low of $39.48 and a fifty-two week high of $64.50. $. The company has a market capitalization of $999.53 million, a P/E ratio of 34.57, a P/E/G ratio of 3.06 and a beta of 1.36. The company’s 50-day moving average is $45.60 and its 200-day moving average is $50.86.

In other LeMaitre Vascular, CFO news Joseph P. Pellegrino, Jr. sold 807 shares of the company in a transaction dated Monday, December 27. The shares were sold at an average price of $52.00, for a total value of $41,964.00. The sale was disclosed in a filing with the Securities & Exchange Commission, available at the SEC website. 16.50% of the shares are currently held by insiders.

A number of hedge funds and other institutional investors have recently changed their LMAT holdings. Point72 Hong Kong Ltd purchased a new equity stake in LeMaitre Vascular during the third quarter worth approximately $54,000. Harbor Investment Advisory LLC acquired a new stock position in LeMaitre Vascular during the third quarter worth approximately $56,000. O Shaughnessy Asset Management LLC raised its position in shares of LeMaitre Vascular by 827.8% in the third quarter. O Shaughnessy Asset Management LLC now owns 1,336 shares of the medical device supplier valued at $71,000 after acquiring 1,192 additional shares last quarter. Man Group plc acquired a new equity stake in LeMaitre Vascular in the second quarter worth approximately $204,000. Finally, Quantinno Capital Management LP acquired a new equity stake in LeMaitre Vascular during the third quarter at a value of approximately $209,000. 85.82% of the shares are held by institutional investors.

LeMaitre Vascular Company Profile (Get a rating)

LeMaitre Vascular, Inc. engages in the provision of medical devices and human tissue cryopreservation services. The company focuses on the design, marketing, sale, service and technical support of medical devices and implants for the treatment of peripheral vascular disease. Its products include balloon catheters, carotid shunts, biopatches, radiopaque marker tapes, anastomotic clips, remote endarterectomy devices, laparoscopic cholecystectomy devices, vascular grafts and powered phlebectomies.

Read more

Get a Free Copy of Zacks’ LeMaitre Vascular (LMAT) Research Report

For more information on Zacks Investment Research’s research offerings, visit Zacks.com

This instant alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]

Should you invest $1,000 in LeMaitre Vascular right now?

Before you consider LeMaitre Vascular, you’ll want to hear this.

MarketBeat tracks Wall Street’s top-rated, top-performing research analysts daily and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market ripples…and LeMaitre Vascular wasn’t on the list.

While LeMaitre Vascular currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.

See the 5 actions here